Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman.
- Author:
Hoon Kyo KIM
1
;
Myeong Im AHN
;
Jinyoung YOO
;
Chi Hong KIM
;
Hong Jun YANG
;
Byoung Yong SHIM
Author Information
1. Department of Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea. chihongk@yahoo.co.kr
- Publication Type:Case Report
- Keywords:
Lung neoplasm;
Targeted therapy;
Erlotinib;
Gefitinib
- MeSH:
Adenocarcinoma*;
Aged;
Female;
Humans;
Lung Neoplasms;
Lung*;
Protein-Tyrosine Kinases;
Erlotinib Hydrochloride
- From:Cancer Research and Treatment
2007;39(1):37-39
- CountryRepublic of Korea
- Language:English
-
Abstract:
A patient with adenocarcinoma of the lung was treated sequentially using two kinds of EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. The patient was a 73-year-old female who received gefitinib as a second line treatment, which resulted in a partial response with response duration of 6 months. After progression of the disease, the patient received erlotinib, which resulted in partial response again with response duration of 11.5 months. This observation suggests that treatment with erlotinib may be effective in patients who develop progressive disease after a primary treatment with gefitinib following an initial response.
